0001630113 false 0001630113 2021-09-08 2021-09-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(D) of The Securities Exchange Act Of 1934

 

Date of report (Date of earliest event reported): September 8, 2021

 

BIOTRICITY INC.
(Exact name of registrant as specified in its charter)

 

Nevada   000-56074   47-2548273

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

275 Shoreline Drive, Suite 150
Redwood City, California 94065
(Address of Principal Executive Offices)

 

(650) 832-1626

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
  Securities registered pursuant to Section 12(b) of the Act: None
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
   
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

   
  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 
 

 

Item 8.01. Other Events.

 

On September 8, 2021, Biotricity Inc., a Nevada corporation (the “Company”), issued a press release announcing that its Chief Executive Officer Mr. Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021. A copy of this press release is attached as Exhibit 99.1

 

Item 9.01 Financial statements and Exhibits

 

(d) Exhibits.

 

Exhibit Number   Description
99.1   Press Release September 08, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: September 10, 2021

 

  BIOTRICITY INC.
   
  By: /s/ John Ayanoglou
    John Ayanoglou
    Chief Financial Officer

 

 

 

Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Biotricity (QB) Charts.
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Biotricity (QB) Charts.